Pushing Boundaries to Revolutionize Chronic Inflammation Therapy
June 14, 2024

By Joe Petroziello — Pharmaceutical Executive

June 13, 2024

Novel approaches against chronic inflammation could potentially prevent certain inflammatory diseases and neurological conditions.

During BIO International Convention 2024, CEO Dave Bearss, PhD, of Halia Therapeutics, discussed the biopharmaceutical company’s progress in inflammation drug discovery. Founded in 2017, Halia Therapeutics supports the discovery and development of novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases.